ClinicalTrials.gg

Program

WRN Inhibitor GSK4418959

Its studies are mostly in Colorectal Neoplasms, led by GlaxoSmithKline.

Furthest: phase 2, since Nov 26, 20241 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 2since Nov 26, 2024Nov 26, 2024none ahead

Also a collaborator on its studies: IDEAYA Biosciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 26, 2024First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT06710847 · 14 enrolled · United States, Australia, Belgium and more

TargetBeta

WRN →read by rule
“An orally bioavailable inhibitor of the Werner syndrome ATP-dependent helicase (WRN), ”NCIt, by rule

Other programs on WRN

ProgramCompanyFurthest phaseStudies
WRN Inhibitor RO7589831ruleBayerphase 22
WRN Inhibitor NDI-219216rulenimbus-wadjet-incphase 21
WRN Inhibitor EIK1005ruleeikon-therapeuticsphase 21
WRN Inhibitor MOMA-341rulemoma-therapeuticsphase 11
WRN Inhibitor AMG 436ruleAmgenphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06710847Colorectal Neoplasms · United States, Australia, Belgium and more2Active, not recruitingJun 22, 202614

How it is read

Names in the registry

  • “GSK4418959”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.